

Appl. No. 09/775,046
Amdt. Dated August 11, 2003
Reply to Office Action of March 11, 2003

IN THE CLAIMS:

Claims 1-3 (Cancelled).

Claim 4. (Currently amended) A method of modulating physiology or development of an IL-1R6 receptor expressing cell comprising contacting said the cell to an exogenous agonist or antagonist of a mammalian IL-1 δ or IL-1 ϵ (SEQ ID NOs:4 or 10), wherein the antagonist is:

- a) a composition derived from the antigen-binding site of an antibody that specifically binds to IL-1 ϵ or IL-1R6 (SEQ ID NOs:13 or 15); or
- b) IL-1 δ (SEQ ID NOs:2 or 11).

Claim 5. (Currently amended) The method of Claim 4, wherein:

- A) said the antagonist is:
 - 1) an antibody which:
 - a) neutralizes said mammalian IL-1 δ ; or
 - b) neutralizes said the mammalian IL-1 ϵ or IL-1R6; or
 - 2) a mutein of said IL-1 δ or IL-1 ϵ ;
- B) said the physiology is selected from:
 - 1) proliferation;
 - 2) tissue remodeling; or
 - 3) production of inflammatory mediators, including cytokines, chemokines, or adhesion molecules; or
- C) said modulating is specific for epithelial cells and not endothelial cells
the cell is an epithelial cell.

Claim 6. (Currently amended) The method of Claim 4 Claim 5, wherein:

- a) said antagonist is an antibody and said the physiology is an inflammatory response; or
- b) said modulating is specific for Th2 cells and not Th1 cells.

Appl. No. 09/775,046
Amdt. Dated August 11, 2003
Reply to Office Action of March 11, 2003

Claim 7. (Currently amended) The method of Claim 4 Claim 6, wherein said the modulating is blocking, and said physiology is an inflammatory response inhibition.

Claim 8. (Currently amended) A method of modulating a signal to a cell mediated by IL-1 δ or IL-1 ϵ (SEQ ID NOs:4 or 10) comprising contacting said the cell to an administered agonist or antagonist of IL-1R6 (SEQ ID NOs:13 or 15), wherein the antagonist is:

- a) a composition derived from the antigen-binding site of an antibody that specifically binds to IL-1 ϵ or IL-1R6; or
- b) IL-1 δ (SEQ ID NOs:2 or 11).

Claim 9. (Currently amended) The method of Claim 8, wherein said the modulating is inhibiting, and said the signal is a pro-inflammatory signal.

a³
Claim 10. (Currently amended) The method of Claim 9 Claim 8, wherein:

- a) said the antagonist is a neutralizing antibody to IL-1 ϵ or IL-1R6;
- b) said agonist or antagonist is administered in combination with an antagonist or agonist of CXCR1, CXCR2, or CCR6; or
- c) said agonist or antagonist is administered in combination with a growth factor, cytokine, chemokine, or immune adjuvant.

Claims 11-20. (Cancelled).